Clinical trial
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR)…
NCT00093080 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00093080 |
|---|---|
| Title | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) |
| Official title | A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Ariad Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leiomyosarcoma, Liposarcoma, Osteosarcoma, Sarcoma, Soft Tissue, Metastases |
| Intervention type | Drug |
| Interventions | ridaforolimus |
| Enrollment | 216 |
| Start date | Oct 1, 2004 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Oct 4, 2004 |
| Last update posted | Feb 13, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: